Cost effectiveness of cardioprotective strategies in patients with aggressive non-Hodgkin's lymphoma

Clinical Drug Investigation

Volumn 25, Issue 11, 2005, Pages 719-729

  Limat, Samuel ^a,b   Demesmay, Karine ^a   Fagnoni, Philippe ^a,b   Voillat, Laurent ^a   Bernard, Yvette ^a   Deconinck, Eric ^a,b   Brion, Annie ^a   Arveux, Patrick ^b   Cahn, Jean Yves ^c   Woronoff Lemsi, Marie Christine ^a,b  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b INSERM   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; LIPOSOME; PREDNISONE; RAZOXANE; VINCRISTINE;

ADULT; AGE; ARTICLE; BIOLOGICAL MODEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DOSE RESPONSE; DRUG COST; ECONOMIC ASPECT; ENCAPSULATION; EPIDEMIOLOGICAL DATA; HEALTH CARE SYSTEM; HEART PROTECTION; HUMAN; LIFE EXPECTANCY; LIFESPAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; THEORETICAL STUDY; TREATMENT OUTCOME;

EID: 27644548569     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200525110-00005     Document Type: Article

References (42)

1. Messori A, Vaiani M, Trippoli S, et al. Survival in patients with intermediate or high-grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer 2001; 84 (3): 303-7
2. Kouroukis T, Browman G, Esmail R, et al. Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non-Hodgkin's lymphoma: a systematic review. Ann Intern Med 2002 Jan; 136 (2): 144-52
3. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002 Jan; 346 (4): 235-42
4. Evans L, Hancock B. Non-Hodgkin lymphoma. Lancet 2003 Jul; 362: 139-46
5. Von Hoff D, Layard M, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-7
6. Felker M, Thompson R, Hare J, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342 (15): 1077-84
7. Berry C, Murdoch D, McMurray J. Economics of chronic heart failure. Eur J Heart Fail 2001; 3: 283-91
8. Venturini M, Michelotti A, Del Mastro L, et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 1996 Dec; 14 (12): 3112-20
9. Swain S, Whaley F, Gerber M, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997 Apr; 15 (4): 1318-32
10. Swain S, Whaley F, Gerber M, et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997 Apr; 15 (4): 1333-40
11. Phillips K, Tannock I. Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. J Clin Oncol 1998 Sep; 16 (9): 3179-90
12. Hensley M, Schuchter L, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999 Oct; 17 (10): 3333-55
13. Batist G, Ramakrishnan G, Sekhar C, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized multicenter trial of metastatic breast cancer. J Clin Oncol 2001 Mar; 19 (5): 1444-54
14. Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002 Jan; 94 (1): 25-36
15. Martino R, Perea G, Caballero M, et al. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. Haematologica 2002 Aug; 87 (8): 822-7
16. Tsavaris N, Kosmas C, Vadiaka M, et al. Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma. Anti-cancer Res 2002 May; 22 (3): 1845-8
17. Limat S, Demesmay K, Voillat L, et al. Early cardiotoxicity of CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol 2003 Feb; 14 (2): 277-81
18. Swain S, Vici P. The current and future role of dexrazoxane as cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 2004 Jan; 130 (1): 1-7
19. McDonagh T, Morrison C, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997 Sep; 350: 829-33
20. Davies M, Hobbs F, Davis R, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 2001 Aug; 358: 439-44
21. Jekerman M, Anderson H, Cavallin-Stahl E, et al. CHOP vs MACOP-B in aggressive lymphoma: a Nordic Lymphoma Group randomised trial. Ann Oncol 1999 Sep; 10 (9): 1079-86
22. Khaled H, Zekri Z, Mokhtar N, et al. A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin's lymphoma patients: long-term results. Ann Oncol 1999 Dec; 10 (12): 1489-92
23. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive NHL: the International non-Hodgkin's lymphoma factors project. N Engl J Med 1993 Sep; 329 (14): 987-94
24. Jong P, Yusuf M, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003 May; 361: 1843-8
25. Kremer L, van Dalen E, Offringa M, et al. Anthracycline-induced clinical heart failure: long-term follow-up study. J Clin Oncol 2001 Jan; 19 (1): 191-6
26. Department of Pharmacy, Besançon University Hospital. Wholesale price-list for drugs. 2002
27. Beck R, Kassirer J, Pauker S. A convenient approximation of life expectancy (The "DEALE"). Validation of the method. Am J Med 1982 Dec; 73: 883-8
28. Beck R, Pauker S, Gottlieb J, et al. A convenient approximation of life expectancy (The "DEALE"): use in medical decision-making. Am J Med 1982 Dec; 73: 889-97
29. Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem cell support. N Engl J Med 2004 Mar; 350 (13): 1287-95
30. Shipp M, Abeloff M, Antman K, et al. International consensus conference on high dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphoma: report of the jury. J Clin Oncol 1999 Jan; 17 (1): 423-9
31. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH-87 protocol-a Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 2000 Aug; 18 (16): 3025-30
32. Blayney D, LeBlanc M, Grogan T, et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 2003 Jul; 21 (13): 2466-73
33. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991 Aug; 325 (5): 293-302
34. Eichhorn E. Prognosis determination in heart failure. Am J Med 2001 May; 110: 14s-35s
35. Organisation for Economic Co-operation and Development. Statistics, data and indicators. Consumer price indices (CPI) for OECD countries [online]. Available from URL: http://www.oecd.org/ [Accessed 2005 May 30]
36. Davey P, Clarkson P, McMahon A, et al. Cost associated with symptomatic systolic heart failure. Pharmacoeconomics 1999 Oct; 16 (4): 399-407
37. Shureiqi I, Cantor S, Lippman S, et al. Clinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy. Br J Cancer 2002; 86: 226-32
38. Hequet O, Le Q, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004 May; 22 (10): 1864-71
39. Earle C, Chapman R, Baker C, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000 Sep; 18 (18): 3302-17
40. Durand-Zaleski I, Bertrand M. The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study. Pharmacoeconomics 2004; 22 Suppl. 4: 19-27
41. Fujimaki K, Maruta A, Yoshida M, et al. Severe toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction. Bone Marrow Transplant 2001 Feb; 27 (3): 307-10
42. Goldfarb N, Weston C, Hartmann C, et al. Impact of appropriate therapy for chronic conditions on direct medical costs and workplace productivity: a review of the literature. Dis Manag 2004; 7 (1): 61-75